Sign in Subscribe
Cystic fibrosis

United States Cystic Fibrosis Therapeutics Market to Witness Strong Growth Through 2033

Strategic Insights

— 2 min read

The United States cystic fibrosis therapeutics market is poised for significant growth, driven by innovation in gene therapy, expanded patient access to CFTR modulators, enhanced awareness, and robust research efforts. The market is expected to reach $2.32 billion in 2024 and further reach $4.72 billion by the end of 2033 at a compound annual growth rate of 8.22 percent during the forecast period of 2025-2033. The growth is fueled by the approval of new treatments, increased investment in research and development, and the establishment of well-structured healthcare infrastructure.

Key Takeaways:

  • The United States has a large population of diagnosed patients, with roughly 40,000 individuals with cystic fibrosis and roughly 100,000 carriers in the country.
  • The market is driven by the approval of new treatments, including CFTR modulators, which have revolutionized the treatment of cystic fibrosis and have dramatically enhanced life expectancy and quality of life.
  • The FDA has approved several treatments in recent years, including Vertex Pharmaceuticals' Trikafta and Vertex Pharmaceuticals' Alyftrek, which offer a more convenient dosing regimen for cystic fibrosis patients.
  • Nonprofit organizations, such as the Cystic Fibrosis Foundation, play a crucial role in driving awareness, research funding, and drug development acceleration, and they provide patient access to clinical trials and enable government and private sector partnerships.
  • The high prevalence of cystic fibrosis in the United States, with one of the highest prevalence rates in the world, has driven the increase in diagnosed cases, extending the therapeutic market.
  • Despite the growth of the market, challenges persist, including the high cost of treatment, which creates a tremendous economic burden for health systems, payers, and patients, reducing access to care, particularly for patients in rural areas.

Statistics:

  • The United States Cystic Fibrosis Therapeutics Market is expected to reach $2.32 billion in 2024.
  • The market is expected to reach $4.72 billion by the end of 2033 at a compound annual growth rate of 8.22 percent during the forecast period of 2025-2033.
  • Roughly 40,000 individuals with cystic fibrosis and roughly 100,000 carriers are in the United States.
  • The FDA has approved several treatments, including Vertex Pharmaceuticals' Trikafta and Vertex Pharmaceuticals' Alyftrek.
  • Nonprofit organizations, such as the Cystic Fibrosis Foundation, provide patient access to clinical trials and enable government and private sector partnerships.
  • The market is driven by innovation in gene therapy, expanded patient access to CFTR modulators, enhanced awareness, and robust research efforts.

Sources:

  • ResearchAndMarkets.com's report, "United States Cystic Fibrosis Therapeutics Market to See Strong Growth Through 2033 - Driven by Gene Therapy and CFTR Innovation."
  • Vertex Pharmaceuticals' website.
  • Cystic Fibrosis Foundation's website.
  • FDA's website.

Read more